Our Technology

Carboxyl-Terminal Peptide (CTP)

Our Carboxyl Terminal Peptide (CTP) technology is used to extend the half-lives of pharmacologically active proteins. CTP uses recombinant technology to fuse a short, naturally occurring 28 amino acid sequence (a CTP) to a pharmacologically active protein which results in slower excretion of the therapeutic protein, thus, extending the protein's half-life. At OPKO, we are currently use CTP technology to treat growth hormone deficiency and in our Factor VIIa product for the management of hemophilia A & B.

Reversible PEGylation

Our reversible PEGylation technology is a novel technique for creating extended release therapeutics. In reversible PEGylation, a conjugate is formed through a proprietary bi-functional hydrolyzable linker, between a drug that contains a primary peptide and a polyethylene glycol (PEG) chain. Once the conjugate enters the bloodstream the linker hydrolyzes at physiological pH and body temperature, releasing the intact drug in a controlled manner. Depending on the peptide or protein, the released molecule can either work locally, systemically or cross the blood brain barrier at receptor sites.

AntagoNAT

In our Natural Antisense Transcripts Antagonist (AntagoNAT) technology, an oligonucleotide molecule is designed to interfere with regulatory gene expression in order to enhance production of endogenous functional proteins. This strategy is unique and contrasts with established approaches which down-regulate protein production. This platform can lead to the discovery of new drugs to target relevant genes that regulate the optimal production of endogenous functional proteins. One of the leading applications of our AntagoNAT technology is OPK88001 which is designed for the treatment of Dravet syndrome by targeting the mutated SCN1A gene.

Claros® 1

The Claros^® 1 device is a point-of-care, bench top diagnostic instrument system designed to provide rapid, quantitative blood test results in 15 minutes, right in the physician's office, using a fingerstick of whole blood. The Sangia Total PSA Claros^® 1 test, which provides measurements comparable to large instruments used in central reference laboratories, received FDA approval in January 2019. Additional test menu options for this platform are planned for future regulatory approval.